Literature DB >> 18645366

Treatment of severe hypercalcemia using continuous renal replacement therapy with regional citrate anticoagulation.

Detlef Kindgen-Milles1, Rainer Kram, Wolfgang Kleinekofort, Stanislao Morgera.   

Abstract

We report a patient with severe hypercalcemia and acute kidney failure, in whom citrate anticoagulation was used not only for anticoagulation but also to correct ionized hypercalcemia (1.77 mmol/L). In this patient, after a complicated surgical procedure, septic shock led to acute kidney failure. We started continuous venovenous hemodialysis with citrate anticoagulation. By almost stopping the calcium substitution during the first hours, elevated systemic ionized calcium decreased into the normal range within 8 hours. Although calcium substitution was then increased, serum ionized calcium decreased to a nadir of 0.86 mmol/L and then stabilized within the normal range within the next 24 hours. To correct the imbalance in systemic ionized calcium concentration, the calcium substitution was varied over a wide range of 0.1-3.0 mmol/L of generated effluent. The time delay between adjustment in calcium infusion rate and the first detectable change in ionized calcium level was below 4 hours. However, the full response to a change of the calcium substitution was found after 8-12 hours.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18645366     DOI: 10.1097/MAT.0b013e31817dc3be

Source DB:  PubMed          Journal:  ASAIO J        ISSN: 1058-2916            Impact factor:   2.872


  8 in total

1.  Fine-tuned continuous renal replacement therapy with calcium-free dialysate to manage severe hypercalcemia refractory to medical and intermittent hemodialysis.

Authors:  Marc Scheen; Grzegorz Nowak; Bienvenido Sanchez; Daniel Teta
Journal:  Eur J Med Res       Date:  2022-06-08       Impact factor: 4.981

2.  Discrepant post filter ionized calcium concentrations by common blood gas analyzers in CRRT using regional citrate anticoagulation.

Authors:  Patrik Schwarzer; Sven-Olaf Kuhn; Sylvia Stracke; Matthias Gründling; Stephan Knigge; Sixten Selleng; Maximilian Helm; Sigrun Friesecke; Peter Abel; Anders Kallner; Matthias Nauck; Astrid Petersmann
Journal:  Crit Care       Date:  2015-09-08       Impact factor: 9.097

3.  Regional citrate anticoagulation versus low molecular weight heparin anticoagulation for continuous venovenous hemofiltration in patients with severe hypercalcemia: a retrospective cohort study.

Authors:  Yan Yu; Ming Bai; Zhang Wei; Lijuan Zhao; Yangping Li; Feng Ma; Shiren Sun
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

4.  Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: the Liver Citrate Anticoagulation Threshold (L-CAT) observational study.

Authors:  Torsten Slowinski; Stanislao Morgera; Michael Joannidis; Thomas Henneberg; Reto Stocker; Elin Helset; Kirsti Andersson; Markus Wehner; Justyna Kozik-Jaromin; Sarah Brett; Julia Hasslacher; John F Stover; Harm Peters; Hans-H Neumayer; Detlef Kindgen-Milles
Journal:  Crit Care       Date:  2015-09-29       Impact factor: 9.097

5.  Severe hypercalcemia as a form of acute lymphoblastic leukemia presentation in children.

Authors:  Andreia Luís Martins; Marta Moniz; Pedro Sampaio Nunes; Clara Abadesso; Helena Cristina Loureiro; Ximo Duarte; Helena Isabel Almeida
Journal:  Rev Bras Ter Intensiva       Date:  2015 Oct-Dec

6.  Treatment of extreme hypercalcaemia: the role of haemodialysis.

Authors:  Anna B Basok; Boris Rogachev; Yosef Shmuel Haviv; Marina Vorobiov
Journal:  BMJ Case Rep       Date:  2018-06-04

7.  A life-threatening duodenal ulcer hemorrhage due to previously unknown primary hyperparathyroidism.

Authors:  Dan Xie; Kunpeng Hu; Ying Xian; Ying Wang; Xiaofeng Yuan; Mingliang Li; Xiaogang Bi; Kouxing Zhang
Journal:  Gastroenterol Rep (Oxf)       Date:  2016-09-10

8.  Rapid calcium loss may cause arrhythmia in hemofiltration with regional citrate anticoagulation: a case report.

Authors:  Buyun Wu; Jing Wang; Guang Yang; Changying Xing; Huijuan Mao
Journal:  BMC Nephrol       Date:  2018-06-14       Impact factor: 2.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.